On September 3, 2026, the FDA posted an update acknowledging it is working with manufacturers to increase the supply of estradiol transdermal patches — while pointedly declining to use the word "shortage." CBS News reported the same day that doctors, patients and a group of Democratic House members are pressing the agency to formally add estradiol patches to its federal drug shortage database, arguing the current listing does not reflect what is actually happening at pharmacy counters. The gap between the agency's language and the pharmacy experience is now the story.

Why It Matters

This is what happens when a regulatory unlock outruns a supply chain. The black-box removal was the single biggest destigmatization event in menopause care in a generation, and it worked — arguably too well for the manufacturing base to absorb. Afterglow has tracked the demand side of this all year: the perimenopause telehealth boom (Midi, Winona, Alloy, Evernow), Hers's April entry into menopause care at $134/month, and Oura pushing its Menopause Impact Scale into ten clinical partners. All of those businesses are downstream of a molecule that patients currently cannot reliably fill. The shortage-declaration fight is not semantic. A formal designation changes manufacturer incentives, opens compounding pathways, and affects insurance handling of partial fills — which is precisely why physicians want it and why the agency's historic-demand methodology, tuned for gradual change, is the wrong instrument for a step function. For sexual-health specifically, estradiol is not only a vasomotor drug: it is the front line for genitourinary syndrome of menopause, vaginal dryness and painful sex, meaning a patch shortage lands directly on sexual function for millions of women. Watch for whether the FDA adds the listing, and whether any of the five-to-six US patch manufacturers announce capacity expansion.

The demand curve is the cause. According to nationwide HealthVerity data cited by CBS, prescriptions for estrogen patches rose from roughly 594,000 in June 2024 to 1.6 million in May 2026 — close to a tripling in under two years. The trigger was regulatory: the FDA removed the 26-year-old "black box" warning from many menopausal hormone therapy products, with labeling changes taking effect in February 2026. Dr. Suzanne Hackenmiller, an Arizona OB-GYN quoted in the report, described the effect plainly: "More women felt safe to use estrogen. More doctors felt safe to prescribe it." Demand for progesterone, often co-prescribed, has grown alongside it, producing uneven supply across both.

The patient-side symptoms are the familiar ones of a shortage that has not been officially declared. Los Angeles patient Diane Harris told CBS she called "every pharmacy I could come up with," began stretching her twice-weekly patches to make supply last, and eventually found a pharmacy more than 25 miles away that could fill the prescription. Hackenmiller has started a petition urging a formal declaration, arguing it would give existing manufacturers an incentive to increase production and potentially draw new entrants. She also flagged a cost consequence: patients normally filling 90-day supplies are being handed 30-day supplies, paying the same copay multiple times for the same quarter of treatment.

The American Society of Health-System Pharmacists, which collects reports directly from pharmacists and providers, currently lists more than a dozen estradiol patch products on its active drug shortage list — a direct contradiction of the FDA database. In their letter to the agency, House lawmakers argued the methodology is the problem: "The FDA relies on historic demand data to determine if drug manufacturers are keeping pace, and these data may be lagging given how quickly demand for the patches has spiked."

The FDA's own framing is notably warm toward the underlying trend even as it resists the shortage label. In its update, the agency said it "views increased interest in menopause treatment as an important development for women's health and is working closely with manufacturers to help ensure that the supply of estradiol patches keeps pace with demand," while maintaining that although availability varies by pharmacy and location, the patches remain available. It recommends patients work with providers and pharmacists to find stock or alternatives.

Sources

Update — 2026-09-05

{Initial entry — story first created.}